Here's a look at some of the noteworthy HIV research being presented at IDWeek 2016 in New Orleans from Oct. 25 to 30.
Flu season can bring anxiety for people living with HIV and their health care providers. But do HIV-positive people have more severe symptoms of flu than people who are not living with HIV? In this interview, Christina Schofield, M.D., shares her stu...
HIV treatment as prevention has become a well-known and powerful tool in the global HIV response. In this interview, Mark Sulkowski, M.D., discusses whether a similar approach could be used in the prevention of hepatitis C.
In this interview, Matthew Perkins, M.D., discusses the interest in post-treatment controllers -- people living with HIV who are able to control the virus for a period of time after stopping therapy -- and the first study such individuals.
In this interview, Eric Daar, M.D. discusses how the new coformulation elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya) measures up to its predecessor, specifically among older adults.
In this interview, Prema Menezes, Ph.D., discusses what motivates people living with HIV to enter into clinical trials and what stops those who have never participated from volunteering.
With more than 20 approved HIV antiretrovirals in the United States, physicians have many options for their patients -- they can choose one of the "preferred" drug regimens or deviate from treatment guidelines entirely.
A new study finds significant health disparities between black and white men with HIV, even though these men had equal access to health care through the Veterans Administration (VA).
Paul Sax, M.D., breaks down another HIV treatment switching study -- this one from IDWeek 2015 -- the results of which supported switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide plus darunavir (Prezista) for treatment-experien...
How do things stand with the development of topical agents for HIV prevention? In the age of oral pre-exposure prophylaxis (PrEP) and treatment as prevention, do microbicides matter anymore?